Table 2. NS5A L31/Y93 RASs in mouse administrated with LDV/GS-558093 treatment and ASV/DCV re-treatment.
| L31-Y93 | L31V-Y93 | L31-Y93H | L31V-Y93H | |
|---|---|---|---|---|
| week 0 | 95.9% | — | — | — |
| week 10 (A) | 3.0% | 4.0% | 90.1% | 0.9% |
| (LDV/GS-558093 post 6 w) | ||||
| week 14 (B) | — | — | 99.4%* | — |
| (LDV/GS-558093 post 10 w) | ||||
| week 26 (C) | — | — | 0.7% | 98.6% |
| (ASV/DCV post 8 w) | ||||
| week 29 | — | — | 17.4% | 75.4% |
| (ASV/DCV post 11 w) | ||||
| week 31 | — | — | 9.0% | 82.9% |
| (ASV/DCV post 13 w) |
*Represents the putative original variants before treatment that contributed to the L31M/V-Y93H double substitution after treatment.